Placental isoferritin: A new biomarker from conception to delivery

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 103, Issue 4, 1996, Pages 301-305

  Maymon, Ron ^a   Moroz, Chaya ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; ISOFERRITIN;

DELIVERY; FEMALE; FETUS; HUMAN; IMMUNOLOGY; MEASUREMENT; PLACENTA; PREGNANCY DISORDER; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; CYTOKINES; FEMALE; FERRITINS; HUMANS; OBSTETRIC LABOR, PREMATURE; PLACENTA; PREGNANCY; PREGNANCY TRIMESTER, FIRST;

EID: 0030009756     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1996.tb09732.x     Document Type: Review

References (29)

1. Drysdale JW. Microheterogeneity of ferritin molecules. Biophys Acta 1970; 207: 256–258.
2. Drysdale JW, Adelman TG, Arosia P, Casareale D, Fitzpatrick P, Hazard JT, Yokota M. Human isoferritins in normal and disease states. Semin Hematol 1971; 14: 71–88.
3. Moroz C, Kahn M, Chaimoff C, Marcus H, Kupfer B, Cuckle HS. Ferritin-bearing lymphocytes in the diagnosis of breast cancer. Cancer 1984; 54: 84–89.
4. Moroz C, Bessler H. A new monoclonal antibody enzymoassay for the specific measurement of placenta-like ferritin in haematologic malignancies. Exp Haematol 1987; 15: 258–262.
5. Moroz C, Bessler H. Ferritin as a marker of malignancy. In: de Soma M, Brock JH, editors. Iron in Immunity, Cancer and Inflammation. New York: John Wiley and Sons Ltd, 1989: 283–299.
6. Moroz C, Misrock SL, Siegal FP. Isoferritins in HIV infection: relation to clinical stage CD8 lymphocyte binding and the pathogenesis of AIDS. AIDS 1989; 3: 11–16.
7. Moroz C, Weisman Z, Kalinkovich A, Bentwich Z. Increased p43-isoferritin in Ethiopian immigrants in Israel: a marker for immune activation [letter]. AIDS 1994; 8: 1355–1356.
8. Drysdale JW, Singer RM. Carcinofetal human isoferritins in placenta and HeLa cells. Cancer Res 1974; 34: 3352–3354.
9. Moroz C, Bessler H, Sirota L, Dulitzky F, Djaldetti M. Difference in the placental ferritin levels measured by a specific monoclonal antibody enzymoassay in preterm and term delivery. Clin Exp Immunol 1987; 69: 702–706.
10. Rosen AC, Rosen HR, Huber K et al. Correlation of placental isoferritin with birthweight and timepoint of first contraction. Gynecol Obstet Invest 1995; 139: 11–14.
11. Marcus DM, Zimberg N. Isolation of ferritin from human mammary and pancreatic carcinomas by means of antibody immunoabsorbents. Arch Biochem Biophys 1974; 162: 493–501.
12. White GP, Worwood M, Parry D, Jacobs A. Ferritin synthesis in normal and leukaemic leukocytes. Nature 1976; 250: 584–586.
13. Hancock BW, Bruce L, May K, Richmond J. Ferritin a sensitizing substance in the leukocyte migration inhibition test in patients with malignant lymphoma. Br J Haematol 1979; 43: 223–233.
14. Moroz C, Kupfer B. Suppressor cell activity of ferritin bearing lymphocytes in patients with breast cancer. Isr J Med Sci 1981; 17: 879–881.
15. Hamn HWL, Stahlhut MW, Chung LC. Inhibitory effects of isoferritins from tumor and nontumor tissue on E-rosette formation. Lancet 1984; 1: 43–44.
16. Matzner Y, Konijn AU, Shlomai Z, Ben-Bassat H. Differential effect of isolated placental isoferritins on in vitro T lymphocyte function. Br J Haematol 1985; 59: 443–448.
17. Moroz C, Kupfer B, Twig S, Parhami-Seren B. Preparation and characterization of mononuclear antibodies specific to placental ferritin. Clin Chim Acta 1985; 114: 111–118.
18. Parhami-Seren B, Moroz C. A unique subunit of placental ferritin identified by the use of monoclonal antibodies. J Path Clin 1986; 1: 17–23.
19. Moroz C, Giller SH, Kupfer B, Urca I. Lymphocytes bearing surface ferritin in patients with Hodgkin's disease and breast cancer. N Engl J Med 1977; 296: 1172.
20. Sirota L, Kupfer B, Moroz C. Placental isoferritin as a physiological downregulator of cellular immunoreactivity during pregnancy. Clin Expl Immunol 1989; 77: 255–262.
21. McIntire JD, Faulk WP. Trophoblast antigens in normal and abnormal human pregnancy. Clin Obstet Gynecol 1987; 29: 976–998.
22. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a T,2 phenomenon Immunol Today 1993; 14: 353–356.
23. Cross JC, Werb Z, Fisher SJ. Implantation and the placenta: key pieces of the development puzzle. Science 1994; 266: 1508–1518.
24. Maymon R, Bahary C, Moroz C. Placental isoferritin measured by specific monoclonal antibody as a predictive marker for pretern contraction outcome. Obster Gynecol 1989; 74: 597–599.
25. Moroz C, Livni E, Siegal J. Treatment of recurrent spontaneous abortions by immunization with paternal lymphocytes induces immunosuppression by placental isoferritin. Am J Reprod Imminol 1993; 30: 32–33.
26. Maymon R, Weinraaub Z, Bukovsky I, Moroz C. Placental isoferritin levels during first trimester of normal and complete molar gestations. Placenta 1995; 16: 455–460.
27. Fukui Y, Ueda H, Hamasaki K, Fujimoto S. Protein secretory patterns of normal and abnormal human placentas with special reference to human chorionic gonadotropin. Acta Anat 1991; 140:254–259.
28. Radetsky P. Stopping premature birth before it's too late. Science 1994; 266: 1486–1488.
29. Maymon R, Bahary C, Moroz C. Placental isofemtin (PLF): a new serum marker in toxemia of pregnancy. Am J Obstet Gynecol patterns of normal and abnormal human placentas with special 1989; 160: 681–684.